YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

Screening Services

Dec. 17, 2007 |  Caliper Life Sciences has launched a new screening service to help researchers determine the efficacy of combination drug therapies and identify potentially harmful combinations before therapies enter clinical trials through their Caliper Discovery Alliances & Services (CDAS). Cellular assays are used to screen for synergistic compound combinations and flag potentially harmful toxicity levels. Assays include Caliper's anti-cancer cell proliferation panel, cellular cytokine/chemokine release assays, or using in vivo efficacy models.

Product: Drug Combination Services through Caliper Discovery Alliances and Services
Company: Caliper Life Sciences
Available: Now
For More Information:

Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.